CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion, and angiogenesis

Molecular and Cellular Biology

Volumn 33, Issue 24, 2013, Pages 4985-4995

  Mellor, Paul ^b   Deibert, Leah ^b   Calvert, Brian ^b   Bonham, Keith ^a,b   Carlsen, Svein A ^a,b   Anderson, Deborah H ^a,b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN 3 LIKE PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CREB3L1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NERVE PROTEIN; TRANSCRIPTOME;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER CELL CULTURE; CELL INVASION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE REPRESSION; GENETIC TRANSFECTION; HYPOXIC CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MIGRATION INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN MICROARRAY; RAT; TUMOR REGRESSION; UNFOLDED PROTEIN RESPONSE; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; DNA MICROARRAY; FEMALE; FISCHER 344 RAT; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; LYMPH NODE METASTASIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE; TUMOR INVASION; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; RATS; RATS, INBRED F344; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84893076854     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00959-13     Document Type: Article

References (51)

1. Zhang K, Kaufman RJ. 2004. Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 279:25935-25938.
2. Pahl HL. 1999. Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol. Rev. 79:683-701.
3. Lee AS. 1992. Mammalian stress response: induction of the glucoseregulated protein family. Curr. Opin. Cell Biol. 4:267-273.
4. Hampton RY. 2000. ER stress response: getting the UPR hand on misfolded proteins. Curr. Biol. 10:R518-R521.
5. Kohno K. 2007. How transmembrane proteins sense endoplasmic reticulum stress. Antioxid. Redox Signal. 9:2295-2303.
6. Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8:519-529.
7. Okamura K, Kimata Y, Higashio H, Tsuru A, Kohno K. 2000. Dissociation of Kar2p/BiP from an ER sensory molecule, Ire1p, triggers the unfolded protein response in yeast. Biochem. Biophys. Res. Commun. 279:445-450.
8. Liu CY, Schroder M, Kaufman RJ. 2000. Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J. Biol. Chem. 275:24881-24885.
9. Shen J, Snapp EL, Lippincott-Schwartz J, Prywes R. 2005. Stable binding of ATF6 to BiP in the endoplasmic reticulum stress response. Mol. Cell. Biol. 25:921-932.
10. Kim R, Emi M, Tanabe K, Murakami S. 2006. Role of the unfolded protein response in cell death. Apoptosis 11:5-13.
11. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. 2007. IRE1 signaling affects cell fate during the unfolded protein response. Science 318:944-949.
12. Szegezdi E, Logue SE, Gorman AM, Samali A. 2006. Mediators of endoplasmic reticulum stress-induced apoptosis.EMBORep. 7:880-885.
13. Kondo S, Murakami T, Tatsumi K, Ogata M, Kanemoto S, Otori K, Iseki K, Wanaka A, Imaizumi K. 2005. OASIS, a CREB/ATF-family member, modulates UPR signalling in astrocytes. Nat. Cell Biol. 7:186-194.
14. Murakami T, Saito A, Hino S, Kondo S, Kanemoto S, Chihara K, Sekiya H, Tsumagari K, Ochiai K, Yoshinaga K, Saitoh M, Nishimura R, Yoneda T, Kou I, Furuichi T, Ikegawa S, Ikawa M, Okabe M, Wanaka A, Imaizumi K. 2009. Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat. Cell Biol. 11:1205-1211.
15. Murakami T, Kondo S, Ogata M, Kanemoto S, Saito A, Wanaka A, Imaizumi K. 2006. Cleavage of the membrane-bound transcription factor OASIS in response to endoplasmic reticulum stress. J. Neurochem. 96:1090-1100.
16. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. 2007. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 67:9809-9816.
17. Jamora C, Dennert G, Lee AS. 1996. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc. Natl. Acad. Sci. U. S. A. 93:7690-7694.
18. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, Glimcher LH, Denko NC, Giaccia AJ, Le QT, Koong AC. 2004. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64:5943-5947.
19. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, Harding H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D, Wouters BG, Koumenis C. 2005. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24:3470-3481.
20. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K. 2004. Effect on tumor cells of blocking survival response to glucose deprivation. J. Natl. Cancer Inst. 96:1300-1310.
21. Carlsen SA, Barry M, Newton K. 1990. The identification of a neutral glycosphingolipid antigenic marker for metastatic cells in the R3230AC rat mammary adenocarcinoma. Clin. Exp. Metastasis 8:141-151.
22. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. 2000. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235.
23. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. 2007. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat 104:13-19.
24. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. 2004. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 64:3479-3485.
25. Chambers AF. 2009. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69:5292-5293.
26. Anderson DH, Ismail PM. 1998. v-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGFbeta receptor. Oncogene 16:2321-2331.
27. Mellor P, Harvey JR, Murphy KJ, Pye D, O'Boyle G, Lennard TW, Kirby JA, Ali S. 2007. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer 97:761-768.
28. Maemura M, Akiyama SK, Woods VL, Jr, Dickson RB. 1995. Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin. Exp. Metastasis 13:223-235.
29. Chamberlain MD, Chan T, Oberg JC, Hawrysh AD, James KM, Saxena A, Xiang J, Anderson DH. 2008. Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation. J. Biol. Chem. 283:15861-15868.
30. Buckley ND, Carlsen SA. 1988. Involvement of soybean agglutinin binding cells in the lymphatic metastasis of the R3230AC rat mammary adenocarcinoma. Cancer Res. 48:1451-1455.
31. Ritchie S, Boyd FM, Wong J, Bonham K. 2000. Transcription of the human c-Src promoter is dependent on Sp1, a novel pyrimidine binding factor SPy, and can be inhibited by triplex-forming oligonucleotides. J. Biol. Chem. 275:847-854.
32. Carlsen SA, Xie Y, Whitfield DM, Pang H, Krepinsky JJ. 1993. Isoglobotetraosylceramide is a marker for highly metastatic cells in rat mammary adenocarcinomas. Cancer Res. 53:2906-2911.
33. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR. 2009. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28:2796-2805.
34. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, Todo S, Hirohashi S. 2002. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. 62:2971-2975.
35. Cifone MA, Fidler IJ. 1980. Correlation of patterns of anchorageindependent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc. Natl. Acad. Sci. U. S. A. 77:1039-1043.
36. Koumenis C, Wouters BG. 2006. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol. Cancer Res. 4:423-436.
37. Mujcic H, Rzymski T, Rouschop KM, Koritzinsky M, Milani M, Harris AL, Wouters BG. 2009. Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiother. Oncol. 92:450-459.
38. Di Sano F, Ferraro E, Tufi R, Achsel T, Piacentini M, Cecconi F. 2006. Endoplasmic reticulum stress induces apoptosis by an apoptosomedependent but caspase 12-independent mechanism. J. Biol. Chem. 281:2693-2700.
39. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, Abate-Shen C. 2008. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68:2132-2144.
40. Scriven P, Brown NJ, Pockley AG, Wyld L. 2007. The unfolded protein response and cancer: a brighter future unfolding? J. Mol. Med. 85:331-341.
41. So AY, de la Fuente E, Walter P, Shuman M, Bernales S. 2009. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev. 28:219-223.
42. Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I. 2005. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab. Invest. 85:408-415.
43. Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y, Ye J. 2011. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe 10:65-74.
44. Macchiarini P, Fontanini G, Dulmet E, de Montpreville V, Chapelier AR, Cerrina J, Ladurie FL, Dartevelle PG. 1994. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann. Thorac. Surg. 57:1534-1539.
45. Hicklin DJ, Ellis LM. 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23:1011-1027.
46. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ. 2002. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 8:3592-3600.
47. Hood JD, Cheresh DA. 2002. Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. Cold Spring Harbor Symp. Quant. Biol. 67:285-291.
48. Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A, Heidenreich A, Weinknecht S, Czubayko F, Zugmaier G. 2003. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann. Oncol. 14:1525-1529.
49. Chang Y, Zuka M, Perez-Pinera P, Astudillo A, Mortimer J, Berenson JR, Deuel TF. 2007. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 104:10888-10893.
50. Ghosh R, Lipson KL, Sargent KE, Mercurio AM, Hunt JS, Ron D, Urano F. 2010. Transcriptional regulation of VEGF-A by the unfolded protein response pathway. PLoS One 5:e9575. doi:10.1371/journal.pone.0009575.
51. Denard B, Lee C, Ye J. 2012. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife 1:e00090. doi:10.7554/eLife.00090.